Eli Lilly (NYSE:LLY) Welcomes Circular Genomics To Gateway Labs For Advancing Alzheimer's Biomarker Research
Circular Genomics recently moved its headquarters to Lilly Gateway Labs, aiming to enhance its Alzheimer's disease ...
Pharmaceutical Technology on MSN6d
Telix’s new lead-212 generator could dispel medical isotope scalability hurdles
Lead-212 is a promising radioactive isotope for use in targeted alpha therapy, an alternative modality to beta-particle-based ...
Insider Monkey7d
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy According to Hedge Funds?
On February 10, the company announced a collaboration with AdvanCell to advance cancer treatment through targeted alpha ...
labiotech16d
The biggest biotech funding rounds in February 2025
Meanwhile, AdvanCell came third in the rankings after raising $112 million in an oversubscribed series C round, which will allow the company to advance ongoing efforts to expand its manufacturing ...
TMCnet20d
Sekisui Specialty Chemicals Achieves ISCC PLUS Certification, Advancing Sustainability in Polymer Production
The company also represents Advancell expandable microspheres, and S-LEC BK polyvinyl acetal resins. Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion dollar, ...
FierceBiotech22d
Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH FXRs, short for farnesoid X receptors, are nuclear receptors mainly expressed in the liver and ...
labiotech24d
Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?
Its licensing agreement with Australian startup AdvanCell was revealed two weeks ago. Leveraging AdvanCell’s Pb-212 production technology and radionuclide development infrastructure and Eli Lilly’s ...